Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* (a) Estimated age ≥ 15 years. Older minimum age is required in some locations. FOR United Kingdom: Estimated or actual age ≥ 16 years FOR Australia: Estimated or actual age ≥ 18 years AND (b) Estimated or actual weight ≥ 50 kg (110 lbs).~* Traumatic injury with confirmed or suspected acute major bleeding and/or Revised Assessment of Bleeding and Transfusion (RABT) score ≥ 2~* Activation of massive transfusion protocol~Exclusion Criteria:~* Healthcare professional cardiopulmonary resuscitation including chest compressions for ≥ 5 consecutive minutes at any time before randomization~* Isolated penetrating or blunt cranial injury, or exposed brain matter~* Isolated burns estimated to be \> 20% total body surface area or suspected inhalational injury~* Known anticoagulation treatment or a history of a TEE, within the past 3 months.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BE1116 (Type: EXPERIMENTAL): Administration by IV infusion
- Placebo (Type: PLACEBO_COMPARATOR): Administration by IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).